Related Experiment Videos
A Claims Data-Based Comparison of Treatment Continuation between Aripiprazole Once-monthly and Paliperidone Palmitate
Chi-Un Pae1,2, So Hyeon Gwon3, Hayeon Kim1
1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Summary
Aripiprazole once-monthly (AOM) showed lower discontinuation rates than paliperidone palmitate once-monthly (PP1M) in schizophrenia patients over 12 months. This real-world study highlights differences in long-acting injectable antipsychotic treatment continuation.
Area of Science:
- Psychiatry
- Pharmacology
- Real-world evidence
Background:
- Long-acting injectable antipsychotics (LAIs) are crucial for schizophrenia treatment.
- Aripiprazole once-monthly (AOM) and paliperidone palmitate once-monthly (PP1M) are widely used LAIs.
- Limited comparative data exist on their long-term treatment continuation.
Purpose of the Study:
- To compare the long-term treatment continuation of AOM versus PP1M in patients with schizophrenia spectrum disorders.
- To assess discontinuation risk and rates between AOM and PP1M over a 12-month period.
Main Methods:
- Retrospective analysis of a nationwide Korean Health Insurance claims database.
- Inclusion of patients with schizophrenia spectrum disorders initiating AOM or PP1M.
- Utilized Cox proportional hazards and Kaplan-Meier analyses for discontinuation assessment.
Main Results:
- AOM demonstrated significantly lower discontinuation risk and rates at both 6 and 12 months compared to PP1M (e.g., 12-month discontinuation: 62.7% for AOM vs. 74.1% for PP1M).
- Numerically lower rates of all-cause hospitalization and newly developed extrapyramidal symptoms were observed with AOM.
- Findings remained consistent across propensity score matching and landmark analyses.
Conclusions:
- Aripiprazole once-monthly (AOM) is associated with a lower risk of treatment discontinuation compared to paliperidone palmitate once-monthly (PP1M) in a real-world setting.
- These findings suggest differential treatment continuation patterns between these two LAIs.
- Further research with robust designs is warranted to confirm these real-world observations.
Related Concept Videos
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:21Methods of Documentation III: PIE
Problem-intervention-evaluation (PIE) is a systematic approach to documentation used in healthcare settings for clinical decision-making and patient care planning. It is a structured approach to organizing patient data based on problems, interventions, and evaluations. Here's a breakdown of its key features and considerations:
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...